Journal Article

The Meteoritics Trial: efficacy of methotrexate after remission-induction with tocilizumab and glucocorticoids in giant cell arteritis—study protocol for a randomized, double-blind, placebo-controlled, parallel-group phase II study

Kreis, Lena, Schmidt, Wolfgang Andreas, Schäfer, Valentin Sebastian, Németh, Robert, Dejaco, Christian, Venhoff, Nils

2024

Overview

Background Glucocorticoids (GC) are the standard treatment for giant cell arteritis (GCA), even though they are associated with adverse side effects and high relapse rates. Tocilizumab (TCZ), an interleukin-6 receptor antagonist, has shown promise in sustaining remission and reducing the cumulative GC dosage, but it increases the risk of infections and is expensive. After discontinuation of TCZ, only about half of patients remain in remission. Additionally, only few studies have been conducted looking at remission maintenance, highlighting the need for alternative strategies to maintain remission in GCA. Methotrexate (MTX) has been shown to significantly decrease the risk of relapse in new-onset GCA and is already a proven safe drug in many rheumatologic diseases. Methods This study aims to evaluate the efficacy and safety of MTX in maintaining remission in patients with GCA who have previously been treated with GC and at least 6 months with TCZ. We hypothesize that MTX can maintain remission in GCA patients, who have achieved stable remission after treatment with GC and TCZ, and prevent the occurrence of relapses. The study design is a monocentric, randomized, double-blind, placebo-controlled, parallel-group phase II trial randomizing 40 GCA patients 1:1 into a MTX or placebo arm. Patients will receive 17.5 mg MTX/matching placebo weekly by subcutaneous injection for 12 months, with the possibility of dose reduction if clinically needed. A 6-month follow-up will take place. The primary endpoint is the time to first relapse in the MTX group versus placebo during the 12-month treatment period. Secondary outcomes include patient- and investigator-reported outcomes and laboratory findings, as well as the prevalence of aortitis, number of vasculitic vessels, and change in intima-media thickness during the study. Discussion This is the first clinical trial evaluating remission maintenance of GCA with MTX after a previous treatment cycle with TCZ. Following the discontinuation of TCZ in GCA, MTX could be a safe and inexpensive drug. Trial registration ClinicalTrials.gov, NCT05623592. Registered on 21 November 2022. EU Clinical Trials Register, 2022-501058-12-00. German Clinical Trials Register DRKS00030571.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Analysis / Antibodies, Monoclonal, Humanized / Biomedicine / Care and treatment / Carotid Intima-Media Thickness / Clinical trials / Clinical Trials, Phase II as Topic / Diagnosis / Dosage and administration / Double-Blind Method / Drug dosages / Giant cell arteritis / Giant Cell Arteritis - diagnosis / Giant Cell Arteritis - drug therapy / Glucocorticoids / Health Sciences / Humans / Immunomodulators / Informed consent / Interleukins / Internal medicine / Ischemia / Magnetic resonance imaging / Medicine / Medicine & Public Health / Methotrexate / Monoclonal antibodies / Neoplasm Recurrence, Local / Randomized Controlled Trials as Topic / Recurrence / Remission (Medicine) / Remission maintenance / Rheumatology / Statistics for Life Sciences / Study Protocol / Tocilizumab / Treatment Outcome / Ultrasonic imaging / Vasculitis / Vein & artery diseases